Robert E Landry Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Robert E Landry.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Robert E Landry. Robert E Landry is EVP Finance CFO in REGENERON PHARMACEUTICALS, INC. ($REGN) and SVP Fin, Dep CFO in REGENERON PHARMACEUTICALS INC ($REGN) and SVP Finance & CFO in REGENERON PHARMACEUTICALS INC ($REGN).
Latest Insider Trading Transactions of Robert E Landry
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 401.70 | 8 | 3,214 | 24,982 | 25 K to 25 K (-0.03 %) |
| Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 400.54 | 21 | 8,411 | 24,990 | 25 K to 25 K (-0.08 %) |
| Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 399.89 | 22 | 8,798 | 25,011 | 25 K to 25 K (-0.09 %) |
| Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 398.63 | 47 | 18,736 | 25,033 | 25.1 K to 25 K (-0.19 %) |
| Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 402.34 | 393 | 158,120 | 25,080 | 25.5 K to 25.1 K (-1.54 %) |
| Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 500 | 136,350 | 25,473 | 25 K to 25.5 K (+2.00 %) |
| Dec 13 2019 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | A | 372.46 | 24,500 | 9,125,270 | 24,500 | |
| Dec 13 2019 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Grant | A | 0.00 | 5,000 | 0 | 24,973 | 20 K to 25 K (+25.03 %) |
| Dec 13 2019 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Grant | A | 0.00 | 2,625 | 0 | 19,973 | 17.3 K to 20 K (+15.13 %) |
| Dec 14 2018 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Option Exercise | A | 381.40 | 20,000 | 7,628,000 | 20,000 | |
| Dec 14 2018 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Grant | A | 0.00 | 12,500 | 0 | 17,348 | 4.8 K to 17.3 K (+257.84 %) |
| Sep 11 2018 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Payment of Exercise | F | 395.29 | 2,251 | 889,798 | 4,848 | 7.1 K to 4.8 K (-31.71 %) |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Option Exercise | A | 378.98 | 23,337 | 8,844,256 | 23,337 | |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Option Exercise | M | 272.70 | 3,000 | 818,100 | 57,000 | |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 499.69 | 100 | 49,969 | 7,099 | 7.2 K to 7.1 K (-1.39 %) |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 498.25 | 100 | 49,825 | 7,199 | 7.3 K to 7.2 K (-1.37 %) |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 496.86 | 100 | 49,686 | 7,299 | 7.4 K to 7.3 K (-1.35 %) |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 496.52 | 74 | 36,742 | 7,399 | 7.5 K to 7.4 K (-0.99 %) |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 496.51 | 100 | 49,651 | 7,473 | 7.6 K to 7.5 K (-1.32 %) |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 501.88 | 89 | 44,667 | 7,573 | 7.7 K to 7.6 K (-1.16 %) |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 500.33 | 100 | 50,033 | 7,662 | 7.8 K to 7.7 K (-1.29 %) |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Payment of Exercise | F | 501.29 | 706 | 353,911 | 7,762 | 8.5 K to 7.8 K (-8.34 %) |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Payment of Exercise | F | 501.29 | 1,631 | 817,604 | 8,468 | 10.1 K to 8.5 K (-16.15 %) |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Buy | M | 272.70 | 3,000 | 818,100 | 10,099 | 7.1 K to 10.1 K (+42.26 %) |
| Sep 01 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Option Exercise | M | 272.70 | 2,000 | 545,400 | 60,000 | |
| Sep 01 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 497.69 | 127 | 63,207 | 7,099 | 7.2 K to 7.1 K (-1.76 %) |
| Sep 01 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 497.42 | 100 | 49,742 | 7,226 | 7.3 K to 7.2 K (-1.37 %) |
| Sep 01 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 489.56 | 100 | 48,956 | 7,326 | 7.4 K to 7.3 K (-1.35 %) |
| Sep 01 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 487.88 | 100 | 48,788 | 7,426 | 7.5 K to 7.4 K (-1.33 %) |
| Sep 01 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Payment of Exercise | F | 486.91 | 454 | 221,057 | 7,526 | 8 K to 7.5 K (-5.69 %) |
| Sep 01 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Payment of Exercise | F | 486.91 | 1,119 | 544,852 | 7,980 | 9.1 K to 8 K (-12.30 %) |
| Sep 01 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Buy | M | 272.70 | 2,000 | 545,400 | 9,099 | 7.1 K to 9.1 K (+28.17 %) |
| Aug 24 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Option Exercise | M | 272.70 | 2,000 | 545,400 | 62,000 | |
| Aug 24 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 478.61 | 100 | 47,861 | 7,099 | 7.2 K to 7.1 K (-1.39 %) |
| Aug 24 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 477.10 | 168 | 80,153 | 7,199 | 7.4 K to 7.2 K (-2.28 %) |
| Aug 24 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 475.53 | 100 | 47,553 | 7,367 | 7.5 K to 7.4 K (-1.34 %) |
| Aug 24 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 474.14 | 100 | 47,414 | 7,467 | 7.6 K to 7.5 K (-1.32 %) |
| Aug 24 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Payment of Exercise | F | 476.10 | 388 | 184,727 | 7,567 | 8 K to 7.6 K (-4.88 %) |
| Aug 24 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Payment of Exercise | F | 476.10 | 1,144 | 544,658 | 7,955 | 9.1 K to 8 K (-12.57 %) |
| Aug 24 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Buy | M | 272.70 | 2,000 | 545,400 | 9,099 | 7.1 K to 9.1 K (+28.17 %) |
| Aug 09 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Option Exercise | M | 272.70 | 2,000 | 545,400 | 64,000 | |
| Aug 09 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 473.57 | 226 | 107,027 | 7,099 | 7.3 K to 7.1 K (-3.09 %) |
| Aug 09 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 472.54 | 100 | 47,254 | 7,325 | 7.4 K to 7.3 K (-1.35 %) |
| Aug 09 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 471.00 | 100 | 47,100 | 7,425 | 7.5 K to 7.4 K (-1.33 %) |
| Aug 09 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 469.91 | 100 | 46,991 | 7,525 | 7.6 K to 7.5 K (-1.31 %) |
| Aug 09 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Payment of Exercise | F | 466.98 | 307 | 143,363 | 7,625 | 7.9 K to 7.6 K (-3.87 %) |
| Aug 09 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Payment of Exercise | F | 466.98 | 1,167 | 544,966 | 7,932 | 9.1 K to 7.9 K (-12.83 %) |
| Aug 09 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Buy | M | 272.70 | 2,000 | 545,400 | 9,099 | 7.1 K to 9.1 K (+28.17 %) |
| Dec 19 2016 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Option Exercise | A | 381.92 | 24,565 | 9,381,865 | 24,565 | |
| Dec 18 2015 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Option Exercise | A | 555.67 | 28,900 | 16,058,863 | 28,900 | |
| Aug 06 2015 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Option Exercise | M | 272.70 | 4,000 | 1,090,800 | 66,000 | |
| Aug 06 2015 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 593.38 | 2,100 | 1,246,098 | 7,099 | 9.2 K to 7.1 K (-22.83 %) |
| Aug 06 2015 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 592.36 | 1,500 | 888,540 | 9,199 | 10.7 K to 9.2 K (-14.02 %) |
| Aug 06 2015 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 591.78 | 400 | 236,712 | 10,699 | 11.1 K to 10.7 K (-3.60 %) |
| Aug 06 2015 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Buy | M | 272.70 | 4,000 | 1,090,800 | 11,099 | 7.1 K to 11.1 K (+56.35 %) |
| Apr 09 2015 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Option Exercise | M | 272.70 | 10,000 | 2,727,000 | 70,000 | |
| Apr 09 2015 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Payment of Exercise | F | 449.50 | 1,835 | 824,833 | 7,099 | 8.9 K to 7.1 K (-20.54 %) |
| Apr 09 2015 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Payment of Exercise | F | 449.50 | 6,066 | 2,726,667 | 8,934 | 15 K to 8.9 K (-40.44 %) |
| Apr 09 2015 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Buy | M | 272.70 | 10,000 | 2,727,000 | 15,000 | 5 K to 15 K (+200.00 %) |
| Dec 18 2014 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Option Exercise | A | 399.66 | 34,000 | 13,588,440 | 34,000 | |
| Sep 11 2013 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Fin, Dep CFO | Option Exercise | A | 272.70 | 80,000 | 21,816,000 | 80,000 | |
| Sep 11 2013 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Fin, Dep CFO | Grant | A | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |